our mission:
to make life
worth living again
for millions of patients.
our mission:
to make life
worth living again
for millions of patients.
company profile
Clexio Biosciences is a clinical-stage pharmaceutical company dedicated to the development of novel treatments designed to deliver clinical benefits to patients through sophisticated integration of drugs and new technologies.
We are currently working on the development of a rich portfolio of five novel programs for the treatment of pain, depression and other CNS indications.
Clexio Biosciences was established in March 2018. Dexcel Pharma Technologies, Elisabeth Kogan, Menashe Levy and Elena Kagan are the Co-founders of Clexio.
quick facts
Pipeline
five novel programs
Types of drugs
small molecules, drugs and
drug-device combinations
Indications
depression, pain and
other CNS indications
Innovation
29 patent families,
7 US granted patents.
Team
A cohesive team of
35 employees, growing.
The power of collaboration
broad network of external partners.
Our team and our partners are the
key ingredients for our success.
We believe in the power of collaboration – both internally and externally.
Our team and partners are the key ingredients in our success.